VivoSeq
Oncology

Recurrent Rectal Cancer

0

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Recurrent Rectal Cancer is an early-stage landscape with 0 programs across 1 company. The most active players are AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed3 · 38%
Recruiting3 · 38%
Unknown status1 · 13%
Not yet recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Induction Chemotherapy for Locally Recurrent Rectal Cancer
Recruiting·—·Phase 3·NCT04389086·364 enrolled
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT06767007·31 enrolled
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
Recruiting·National Cancer Center Hospital East·Phase 3·NCT04288999·110 enrolled
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer
Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT06751394·44 enrolled
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer
Completed·—·N/A·NCT02528175·6 enrolled
A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00590278·49 enrolled
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00084773·28 enrolled
SGM-101 in Locally Advanced and Recurrent Rectal Cancer
Unknown status·LLeiden University Medical Center·Phase 2/3·NCT04642924·203 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)